• Grzegorz Procyk, Marcin Grabowski, and Aleksandra Gąsecka.
• Pol. Arch. Med. Wewn. 2025 Jan 10.

IntroductionAtrial fibrillation (AF) is the most prevalent form of cardiac arrhythmia worldwide. Early diagnosis and treatment are essential, emphasizing the need to develop novel biomarkers. Lipoprotein(a) [Lp(a)] has recently been widely investigated as a potential risk factor for various cardiovascular conditions, including AF.ObjectivesThe study's objective is to systematically review the current knowledge about the role of Lp(a) in AF.MethodsThis systematic review adhered to the PRISMA 2020 guidelines. Full-text original clinical studies in English assessing the role of Lp(a) in AF were included. Systematic reviews, meta-analyses, reviews, case reports, letters to editors, commentaries, conference abstracts, guidelines/statements, expert opinions, and preprints were excluded. A comprehensive search was conducted across five databases on October 22, 2024: Embase, MEDLINE Ultimate, PubMed, Scopus, and Web of Science. The search yielded 26 original, relevant clinical research articles included in this study.ResultsStudies investigating the association between Lp(a) level and the incidence of AF present conflicting findings. However, Mendelian randomization studies advocate a causal association between high Lp(a) and AF. Data suggests that AF patients who experience a stroke or other thromboembolic events tend to have higher Lp(a) concentrations than those without such events.ConclusionsExisting evidence suggests Lp(a) may play a pathophysiological role in AF patients, especially among patients who experience thromboembolic events. Nevertheless, this field requires further research due to inconsistencies in the existing evidence.

14 keywords...

hide…